137 related articles for article (PubMed ID: 15050738)
1. Genotype relationships in the CYP3A locus in Caucasians.
Dally H; Bartsch H; Jäger B; Edler L; Schmezer P; Spiegelhalder B; Dienemann H; Drings P; Kayser K; Schulz V; Risch A
Cancer Lett; 2004 Apr; 207(1):95-9. PubMed ID: 15050738
[TBL] [Abstract][Full Text] [Related]
2. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
3. A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1.
Rodriguez-Antona C; Axelson M; Otter C; Rane A; Ingelman-Sundberg M
J Biol Chem; 2005 Aug; 280(31):28324-31. PubMed ID: 15937338
[TBL] [Abstract][Full Text] [Related]
4. Genotype of CYP3AP1 associated with CYP3A activity in Chinese Han population.
Zhu B; Chen GL; Chen XP; He N; Liu ZQ; Jiang CH; Wang D; Zhou HH
Acta Pharmacol Sin; 2002 Jun; 23(6):567-72. PubMed ID: 12060534
[TBL] [Abstract][Full Text] [Related]
5. Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers.
Rodríguez-Antona C; Jande M; Rane A; Ingelman-Sundberg M
Clin Pharmacol Ther; 2005 Apr; 77(4):259-70. PubMed ID: 15903124
[TBL] [Abstract][Full Text] [Related]
6. Ethnic differences between Japanese and Caucasians in the expression levels of mRNAs for CYP3A4, CYP3A5 and CYP3A7: lack of co-regulation of the expression of CYP3A in Japanese livers.
Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Saito T; Parkinson A; Nakagawa K; Kamataki T
Xenobiotica; 2005 Jan; 35(1):69-83. PubMed ID: 15788369
[TBL] [Abstract][Full Text] [Related]
7. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose.
Dally H; Edler L; Jäger B; Schmezer P; Spiegelhalder B; Dienemann H; Drings P; Schulz V; Kayser K; Bartsch H; Risch A
Pharmacogenetics; 2003 Oct; 13(10):607-18. PubMed ID: 14515059
[TBL] [Abstract][Full Text] [Related]
8. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population.
Hiratsuka M; Takekuma Y; Endo N; Narahara K; Hamdy SI; Kishikawa Y; Matsuura M; Agatsuma Y; Inoue T; Mizugaki M
Eur J Clin Pharmacol; 2002 Sep; 58(6):417-21. PubMed ID: 12242601
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD
Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism.
Westlind-Johnsson A; Malmebo S; Johansson A; Otter C; Andersson TB; Johansson I; Edwards RJ; Boobis AR; Ingelman-Sundberg M
Drug Metab Dispos; 2003 Jun; 31(6):755-61. PubMed ID: 12756208
[TBL] [Abstract][Full Text] [Related]
11. Molecular population genetics of human CYP3A locus: signatures of positive selection and implications for evolutionary environmental medicine.
Chen X; Wang H; Zhou G; Zhang X; Dong X; Zhi L; Jin L; He F
Environ Health Perspect; 2009 Oct; 117(10):1541-8. PubMed ID: 20019904
[TBL] [Abstract][Full Text] [Related]
12. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene.
Gellner K; Eiselt R; Hustert E; Arnold H; Koch I; Haberl M; Deglmann CJ; Burk O; Buntefuss D; Escher S; Bishop C; Koebe HG; Brinkmann U; Klenk HP; Kleine K; Meyer UA; Wojnowski L
Pharmacogenetics; 2001 Mar; 11(2):111-21. PubMed ID: 11266076
[TBL] [Abstract][Full Text] [Related]
13. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.
Goh BC; Lee SC; Wang LZ; Fan L; Guo JY; Lamba J; Schuetz E; Lim R; Lim HL; Ong AB; Lee HS
J Clin Oncol; 2002 Sep; 20(17):3683-90. PubMed ID: 12202670
[TBL] [Abstract][Full Text] [Related]
14. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.
Wandel C; Witte JS; Hall JM; Stein CM; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2000 Jul; 68(1):82-91. PubMed ID: 10945319
[TBL] [Abstract][Full Text] [Related]
15. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype.
Lee SJ; Bell DA; Coulter SJ; Ghanayem B; Goldstein JA
J Pharmacol Exp Ther; 2005 Apr; 313(1):302-9. PubMed ID: 15634941
[TBL] [Abstract][Full Text] [Related]
16. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations.
Gervasini G; Vizcaino S; Gasiba C; Carrillo JA; Benitez J
Ther Drug Monit; 2005 Dec; 27(6):819-21. PubMed ID: 16306861
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
[TBL] [Abstract][Full Text] [Related]
18. Genetics of the variable expression of CYP3A in humans.
Wojnowski L
Ther Drug Monit; 2004 Apr; 26(2):192-9. PubMed ID: 15228164
[TBL] [Abstract][Full Text] [Related]
19. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.
Plummer SJ; Conti DV; Paris PL; Curran AP; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):928-32. PubMed ID: 14504207
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups.
Li D; Zhang GL; Lou YQ; Li Q; Wang X; Bu XY
J Clin Pharm Ther; 2007 Feb; 32(1):89-95. PubMed ID: 17286792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]